Altimmune to Present at Upcoming Scientific Conferences
Details on the
|Title:||AdCOVID – A Single-Dose Intranasal Vaccine for COVID-19|
Details on the Chronic Hepatitis B Drug Development Virtual Summit presentation are as follows:
|Title:||How We Can Achieve Success with Immunotherapeutics in the Treatment of Chronic Hepatitis B|
A copy of the presentation materials will be accessible on the Events section of the Altimmune website.
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
Altimmune Investor & Media Contacts:
|Chief Financial Officer||Sr. Dir, Investor Relations|
|Phone: 240-654-1450||Phone : 410-474-8200|
Source: Altimmune, Inc.